FDA whistle-blower shifts Arcoxia debate to Europe

FDA whistle-blower isn’t content with helping the fight to keep Merck’s drug Arcoxia off the U.S. market; he’s beginning to move the fight to the other 63 countries where the arthritis medication is sold. The whistle-blower warned that Arcoxia would be a potential public health disaster because it raises heart attack and stroke risk. The panel voted 20 to 1 against recommending approval of the drug, which critics have compared to the infamous Merck drug Vioxx.

For the full article.

Lawyer Monthly - Legal Awards Winner
The National Trial Lawyers
Elder Care Matters Alliance
American Association for Justice
Fellow Litigation Counsel of America
Super Lawyers